High Intensity Focused Ultrasound (HIFU) Ablation System Study
The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs...
Brief Summary
Official Title: “Study of Focused Circumferential UltraSound for the Treatment of Atrial Fibrillation”
The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs.
- Study Type: Interventional
- Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
- Study Primary Completion Date: December 2010
Detailed Clinical Trial Description
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting an estimated 2.2 million persons in the United States (US). In addition to being debilitating, AF has been identified as a leading risk factor for stroke. AF is often associated with structural heart disease, but a substantial number of AF patients have little or no detectable structural heart disease. A patient with AF is up to 5 times more likely to have a stroke than the general population.
Recently, it has been demonstrated that for a significant portion of AF patients (80% - 95 %) the arrhythmia originates in one of the four pulmonary veins (PV's). Furthermore, it has been shown that isolation of this arrhythmia by ablation can, in the majority of patients (50-70%), eliminate or markedly reduce episodes of AF. Currently, there are a number of modalities being investigated to treat AF. They include radiofrequency, laser, thermal, cryo, microwave, and ultrasound ablation of targeted areas in the atrium and/or PVs.
Comparison(s): Clinical success of High Intensity Focused Ultrasound (HIFU) Ablation for Pulmonary Vein Isolation in the treatment of Atrial Fibrillation, compared to medical therapy with anti-arrhythmic drugs (AADs).
Intervention(s) in this Clinical Trial
- Drug: propafenone
- Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
- Drug: flecainide
- Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
- Drug: dofetilide
- Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
- Drug: sotolol
- Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
- Device: Pulmonary vein ablation
- Electrical isolation of pulmonary vein with high-intensity focused ultrasound
- Drug: Amiodarone
- Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
Arms, Groups and Cohorts in this Clinical Trial
- Active Comparator: Control
- Class I or III anti-arrhythmic drug for the treatment of AF
- Experimental: Treatment
- Pulmonary vein ablation with HIFU
Outcome Measures for this Clinical Trial
Primary Measures
- Acute treatment with elimination of AF episodes
- Time Frame: 12 months
Safety Issue?: No
- Time Frame: 12 months
- Death, stroke, and hospitalization for recurrence of AF
- Time Frame: within 12 months of treatment
Safety Issue?: Yes
- Time Frame: within 12 months of treatment
Secondary Measures
- Acute treatment success
- Time Frame: 60 days
Safety Issue?: No
- Time Frame: 60 days
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Documented atrial fibrillation
- Failed or intolerant to at least 1 anti-arrhythmic drug
- Able to take anti-coagulant therapy
- Able to complete screening tests required for inclusion/
exclusion criteria
- Able to take at least 1 approved anti-arrhythmic drug
- Not pregnant
- Available for follow-up for at least 12 months
Exclusion Criteria:
- Persistent or permanent atrial fibrillation
- Mitral disease
- Prior surgical treatment for atrial fibrillation
- Ablation for treatment of atrial fibrillation within 6 months
- Severe left ventricular hypertrophy
- Known untreated coagulopathy
- Unstable angina
- Prior stroke
- Uncontrolled heart failure
- Secondary causes of atrial fibrillation
- Uncorrected hyperthyroidism within 12 months
- Pulmonary embolism within 6 months
- Pneumonia or acute pulmonary disease within 3 months
- Pacemaker/ICD
- High risk for esophageal disease
- Currently enrolled in investigational drug or device study
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 70 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: ProRhythm, Inc. Industry
Overall Clinical Trial Officials and Contacts
Warren Jackman, MD Principal Investigator Oklahoma University Health Sciences Center
Additional Information
Information obtained from ClinicalTrials.gov on February 09, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00392106
Study ID Number: CLIN-003
ClinicalTrials.gov Identifier: NCT00392106
Health Authority: United States: Food and Drug Administration
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00392106
